EU medtech discussions on the move again
This article was originally published in RAJ Devices
Now that the new European Commission has been appointed, it is as if the traffic lights have moved from red to amber. Appointments have been made, and although many decisions have yet to be formally taken before the lights turn green to move forward again, the shape of the future agenda for medical devices is becoming clearer, and to some extent, maybe, also the direction that is likely to take.
You may also be interested in...
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.
February sees some vitally important issues on the European Commission’s agenda, including areas where the medtech sector has been clamoring for progress in terms of clarity over the Commission's thinking and guidance documents. This year's meetings are plentiful and critical.
While the EU has selected the CND system as the basis for its nomenclature, GMDN is becoming increasingly valued on the US and international scene. How does it see its latest role panning out globally?